- Pfizer sees $15 billion revenue from the Pfizer/BioNTech COVID vaccine in 2021 and it could completely change Pfizer’s revenue and earnings trajectory. Think about what this will do for BioNTech.
- The above revenues are for the “pandemic phase.” Pfizer/BioNTech may be considering a 3-4x price increase for their COVID-19 vaccine(s) after this phase. Read this sentence again.
- Not a lot of progress on treatments, but Viraleze, a convenient nasal spray from Starpharma for prevention/early treatment may complement vaccine programs.
For further details see:
COVID-19 Continues, But Good Times For mRNA Vaccine Developers Pfizer/BioNTech And Moderna